Adoptive immunotherapy with donor lymphocyte infusionsafter allogeneic HPC transplantation

due to the loss of the graft-versus-leukemia (GVL) effect thathas been recognized as an important component of theanti-leukemic efficacy of allogeneic HPC transplantation,particularly for chronic myelogenous leukemia (CML). Thedemonstration of this GVL effect and of the primordial roleof T-lymphocytes led investigators to transfuse donor lym-phocytes to CML patients relapsing after HPC transplanta-tion.

[1]  W. M. Smit,et al.  Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. , 1999, Blood.

[2]  M. Boccadoro,et al.  Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy , 1999 .

[3]  A. Tosti,et al.  Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.

[4]  P. Moss,et al.  Tetrameric HLA class I–minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease , 1999, Nature Medicine.

[5]  R. Storb,et al.  Mixed Hematopoietic Chimerism after Marrow Allografts Transplantation in the Ambulatory Care Setting , 1999, Annals of the New York Academy of Sciences.

[6]  R. Verdijk,et al.  Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. , 1999, Blood.

[7]  E. Engleman,et al.  Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. , 1999, Blood.

[8]  Y. Aizawa,et al.  Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients , 1999, Leukemia.

[9]  B. Branger,et al.  Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin’s lymphoma , 1999, Bone Marrow Transplantation.

[10]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[11]  J. Goldman,et al.  The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. , 1998, Blood.

[12]  N. Ueno,et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Schepers,et al.  Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions , 1998, Bone Marrow Transplantation.

[14]  A. Nagler,et al.  Selective CD4+ T-cell depletion does not prevent graft-versus-host disease. , 1998, Transplantation.

[15]  W. Yokoyama.  Natural killer cell receptors. , 1998, Current opinion in immunology.

[16]  D. Neuberg,et al.  Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. , 1998, Blood.

[17]  F. Lemonnier,et al.  Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. , 1998, The Journal of clinical investigation.

[18]  D. Taub,et al.  Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. , 1998, The Journal of clinical investigation.

[19]  E. Warren,et al.  Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. , 1998, Blood.

[20]  A. Nagler,et al.  Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major. , 1998, Journal of pediatric hematology/oncology.

[21]  N. Young,et al.  T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect , 1998, Bone Marrow Transplantation.

[22]  K. Tadokoro,et al.  Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. , 1998, Blood.

[23]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[24]  A. Barrett,et al.  Regulation of a Graft-Versus-Leukemia Effect by Major Histocompatibility Complex Class II Molecules on Leukemia Cells: HLA-DR1 Expression Renders K562 Cell Tumors Resistant to Adoptively Transferred Lymphocytes in Severe Combined Immunodeficiency Mice/Nonobese Diabetic Mice , 1997 .

[25]  J. Cornelissen,et al.  Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. , 1997, Blood.

[26]  M. Seto,et al.  Complete cytogenetic response with host-derived hematopoiesis induced by cyclosporin A discontinuation in a patient with relapsed chronic myelogenous leukemia after bone marrow transplantation , 1997, Bone Marrow Transplantation.

[27]  S. Singhal,et al.  Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients , 1997, Bone Marrow Transplantation.

[28]  A. Barrett.  Mechanisms of the Graft‐versus‐Leukemia Reaction , 1997, Stem cells.

[29]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[30]  K. Lucas,et al.  Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allografts , 1997, Immunological reviews.

[31]  O. Haas,et al.  Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. , 1997, Blood.

[32]  P. Greenberg,et al.  Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. , 1997, Blood.

[33]  E. Holler,et al.  Adoptive immunotherapy with donor lymphocyte transfusions. , 1997, Current opinion in oncology.

[34]  N. Schmitz,et al.  Allogeneic MHC‐mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft‐versus‐leukaemia effect in mice , 1997, British journal of haematology.

[35]  B. Barlogie,et al.  Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. , 1997, Blood.

[36]  K. Kliche,et al.  Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. , 1997, Blood.

[37]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Nagler,et al.  Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. , 1996, Clinical transplants.

[39]  G. Fillet,et al.  Spontaneous complete remission and recovery of donor haemopoiesis without GVHD after relapse and apparent marrow graft rejection in poor‐prognosis myelodysplastic syndrome , 1996, British journal of haematology.

[40]  B. Chapuis,et al.  Donor lymphocyte infusion for a patient with relapsing myelodysplastic syndrome after allogeneic bone marrow transplantation [letter] , 1996 .

[41]  A. Barrett,et al.  Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen , 1996, British journal of haematology.

[42]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[43]  A. Sette,et al.  Specific human cellular immunity to bcr-abl oncogene-derived peptides. , 1996, Blood.

[44]  B. Glass,et al.  Graft‐versus‐leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells , 1996, British journal of haematology.

[45]  A. Nagler,et al.  Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT. , 1996, Blood.

[46]  Craig W. Reynolds,et al.  Gene transfer applied to the modulation of alloreactivity. , 1996, Hematology and cell therapy.

[47]  B. Barlogie,et al.  Graft-versus-myeloma effect: proof of principle. , 1996, Blood.

[48]  H. V. van Houwelingen,et al.  Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. , 1996, The New England journal of medicine.

[49]  H. Kantarjian,et al.  CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. , 1995, Blood.

[50]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[51]  S. Mackinnon,et al.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.

[52]  C. Melief,et al.  Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. , 1995, Leukemia.

[53]  J. Thompson,et al.  Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. , 1995, Bone marrow transplantation.

[54]  J. Falkenburg,et al.  Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. , 1995, The Journal of clinical investigation.

[55]  G. Freeman,et al.  Role of B7-1 in mediating an immune response to myeloid leukemia cells. , 1995, Blood.

[56]  P. Duffey,et al.  Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor , 1995, The Lancet.

[57]  H. Heslop,et al.  Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. , 1995, Journal of hematotherapy.

[58]  R. Krance,et al.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.

[59]  J. Gribben,et al.  Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. , 1994, Blood.

[60]  H. Heslop,et al.  Donor T cells to treat EBV-associated lymphoma. , 1994, The New England journal of medicine.

[61]  J. Goldman,et al.  Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. , 1994, Blood.

[62]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[63]  P. Tiberghien,et al.  Variability of the alloreactive T-cell response to human leukemic blasts. , 1994, Leukemia.

[64]  T. Reichert,et al.  SELECTIVE DEPLETION OF CD8+ CELLS FOR PREVENTION OF GRAFT‐VERSUS-HOST DISEASE AFTER BONE MARROW TRANSPLANTATION A RANDOMIZED CONTROLLED TRIAL , 1994, Transplantation.

[65]  D. Porter,et al.  Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. , 1994, The New England journal of medicine.

[66]  T. Smetsers,et al.  Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  J. Szer,et al.  Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. , 1993, Bone marrow transplantation.

[68]  J. Ferrara,et al.  Cytokine dysregulation and acute graft-versus-host disease. , 1992, Blood.

[69]  H. Kantarjian,et al.  Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation , 1992, British journal of haematology.

[70]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[71]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[72]  A. Nagler,et al.  Control of relapse due to minimal residual disease (MRD) by cell-mediated cytokine-activated immunotherapy in conjunction with bone marrow transplantation. , 1991, Bailliere's clinical haematology.

[73]  R. Champlin.  T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. , 1990, Hematology/oncology clinics of North America.

[74]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[75]  K. Sullivan,et al.  Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. , 1989, The New England journal of medicine.

[76]  R. Hoffmann,et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .

[77]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[78]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[79]  D. Chisholm,et al.  Serum Gastrin in Patients with Peptic Ulceration , 1970, British medical journal.

[80]  J. Loutit,et al.  Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.

[81]  G. Freeman,et al.  Role of B 7-1 in Mediating an Immune Response to Myeloid Leukemia Cells , 2002 .

[82]  M. Boccadoro,et al.  Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. , 1999, Blood.

[83]  F. Lemonnier,et al.  Cytotoxic T Cell Response Against the Chimeric p 210 BCR – ABL Protein in Patients with Chronic Myelogenous Leukemia , 1998 .

[84]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[85]  B. Chapuis,et al.  Donor lymphocyte infusion for a patient with relapsing myelodysplastic syndrome after allogeneic bone marrow transplantation. , 1996, Blood.

[86]  M. Horowitz,et al.  Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. , 1994, Blood.

[87]  M. Horowitz,et al.  Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. , 1993, Blood.

[88]  G. Tricot,et al.  Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. , 1991, Transplantation proceedings.

[89]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[90]  R. Nuscher,et al.  Bone marrow transplantation. , 1977, The American journal of nursing.